Atara Biotherapeutics, Inc.
ATRA
$7.32
-$0.28-3.68%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 32.75M | 40.19M | 28.64M | 27.36M | 4.25M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 32.75M | 40.19M | 28.64M | 27.36M | 4.25M |
| Cost of Revenue | 35.52M | 51.53M | 37.60M | 44.10M | 47.14M |
| Gross Profit | -2.76M | -11.34M | -8.96M | -16.74M | -42.89M |
| SG&A Expenses | 9.44M | 10.42M | 8.91M | 9.76M | 10.39M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 44.96M | 61.95M | 46.52M | 53.85M | 57.53M |
| Operating Income | -12.20M | -21.76M | -17.88M | -26.50M | -53.28M |
| Income Before Tax | -12.71M | -21.93M | -19.05M | -31.73M | -60.44M |
| Income Tax Expenses | -19.00K | -17.00K | -- | 24.00K | 11.00K |
| Earnings from Continuing Operations | -12.69M | -21.91M | -19.05M | -31.75M | -60.45M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -12.69M | -21.91M | -19.05M | -31.75M | -60.45M |
| EBIT | -12.20M | -21.76M | -17.88M | -26.50M | -53.28M |
| EBITDA | -11.10M | -20.53M | -16.55M | -25.11M | -52.07M |
| EPS Basic | -1.19 | -2.93 | -3.10 | -5.65 | -13.98 |
| Normalized Basic EPS | -0.74 | -1.84 | -1.90 | -3.00 | -7.77 |
| EPS Diluted | -1.19 | -2.93 | -3.10 | -5.65 | -13.98 |
| Normalized Diluted EPS | -0.74 | -1.84 | -1.90 | -3.00 | -7.77 |
| Average Basic Shares Outstanding | 10.71M | 7.47M | 6.14M | 5.62M | 4.33M |
| Average Diluted Shares Outstanding | 10.71M | 7.47M | 6.14M | 5.62M | 4.33M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |